News >

Key Trials Showcase the Utility of Neratinib in HER2+ Breast Cancer

Caroline Seymour
Published: Friday, Jul 19, 2019

Michel Velez, MD, a medical oncologist at Holy Cross Hospital

Michel Velez, MD

Given the number of prophylactic interventions that are now available, counseling patients with early-stage HER2-positive breast cancer on the benefit of extended adjuvant therapy with neratinib (Nerlynx) or considering its use in those with central nervous system metastases could be beneficial, said Michel Velez, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication